MedTrace Logo

Pathophysiological Implications of the Incretin Hormones in Patients With Liver Disease With and Without Diabetes

NCT01492283 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2014-07-10

No results posted yet for this study

Summary

The main objective of this study is to analyze the pathophysiological implications of glucagon and the incretin hormones in patients with liver disease (Non alcoholic fatty liver disease (NAFLD) or cirrhosis) with and without diabetes compared with healthy controls. The present study will contribute significantly to the understanding of the pathophysiology of liver disease and glucose metabolism. The final goal is that the results could pave the way for new treatment modalities for patients with liver disease.

Conditions

Interventions

OTHER

OGTT

50g waterfree glucose dissolved in 300 ml water consumed over 5 min.

OTHER

IIGI

iso glycemic intravenous (iv) glucose infusion (IIGI) with 20% glucose

Sponsors & Collaborators

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Principal Investigators

  • Anders E Junker, MD, phd-student · Diabetes Research Division, Gentofte Hospital, University of Copenhagen

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2013-05-31
Completion
2014-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01492283 on ClinicalTrials.gov